Article 2 0f 3
In Article One, we met Carol — a healthy 54-year-old woman in Ashland whose subtle cognitive changes were dismissed as normal aging. We introduced the science showing that Alzheimer’s is in many ways a midlife disease for women, and that the hormonal transition of menopause may be a central driver of women’s dramatically higher risk.
In this article, we go deeper into that connection: what is actually happening in the brain during menopause, what the evidence says about hormone therapy, what options currently exist in Southern Oregon, and what is missing.
The Brain Is an Endocrine Organ — It Runs on Hormones
Most of us think of menopause as something that happens to the ovaries, the uterus, maybe the skin and bones. What the latest neuroscience is revealing is that menopause is, first and foremost, a brain event.
The brain is saturated with estrogen receptors — molecular docking ports that receive estrogen and use it to regulate everything from energy production to inflammation to the growth of new neural connections. The hippocampus, the brain’s memory center, is one of the most estrogen-responsive regions in the entire body. The frontal cortex — the seat of executive function, planning, attention — is similarly well-equipped to receive and use estrogen.
Think of estrogen as a building superintendent for the brain. When the superintendent is present and active, things get fixed. The boiler (mitochondria) runs efficiently, the wiring (neural connections) stays intact, the immune system (microglia) stays calibrated. When the superintendent leaves abruptly, things begin to deteriorate — slowly at first, then faster, in ways that take years to become visible.
Dr. Mosconi’s laboratory at Weill Cornell has developed a remarkable new tool: a brain scan that can actually measure the density of estrogen receptors in the living human brain. What this research has revealed challenges decades of assumptions based on rat studies. In women, estrogen receptor density does not simply crash after menopause. Instead, the brain appears to upregulate — to make more receptors — as estrogen levels fall, in a kind of desperate compensatory reach. This response, at least in Dr. Mosconi’s studies, appears to persist until at least age 65.
What this may mean for treatment is enormous. It suggests that the brain remains, for longer than previously thought, capable of responding to estrogen — that the window for intervention is wider than the standard “start within the first year of menopause or don’t bother” doctrine that many women have been told.
The Women’s Health Initiative: A Study That Cost Women Decades
To understand where we are today on hormone therapy, you have to understand what happened in 2002.
The Women’s Health Initiative (WHI) was a landmark clinical trial, and when preliminary results were published, they set off a panic that reverberated through medicine for over two decades. Headlines announced that hormone replacement therapy caused breast cancer, heart disease, and dementia. Women by the millions stopped their prescriptions overnight. Physicians stopped prescribing. Medical students were taught that hormones were dangerous.
The problem is that the study’s primary hormone regimen used a combination of oral conjugated equine estrogen — derived from horse urine — and a synthetic progestin called medroxyprogesterone acetate (MPA). MPA has since been shown to have its own vascular and potentially carcinogenic properties. The oral delivery of estrogen carries different risks than transdermal (skin patch or gel) delivery, partly because of how it is processed by the liver. And critically, the average age of women enrolled in the study was 63 — many of them a decade or more past menopause, a group for whom the timing considerations of hormone therapy are very different.
Subsequent analyses of the same WHI data, published years later in JAMA, found that not a single additional woman died of breast cancer as a result of even the combined hormone therapy. For women who had undergone hysterectomy and took estrogen alone, there was actually a reduced incidence of breast cancer. These findings received almost no media attention.
The science has moved on from 2002. Much of the medical establishment — particularly the primary care system that most women in Southern Oregon depend on — has not fully caught up.
What the Evidence Actually Shows About Hormones and the Brain
Here is a fair summary of where the science stands today on hormone therapy and Alzheimer’s risk:
Women who start hormone therapy within 10 years of their final menstrual period, particularly those who have had a hysterectomy and take estrogen alone, show approximately a 32% reduced risk of Alzheimer’s disease and dementia in observational studies. This finding is consistent across multiple large datasets and meta-analyses.
For women with a uterus (who take estrogen combined with progesterone), the protective effect is smaller and less consistent — approximately a 23% trend-level reduction — likely because the type of progestin matters enormously. MPA, the synthetic progestin used in the WHI, carries risks that micronized progesterone (the bioidentical form used today) does not.
Women who start hormone therapy more than 10 years after menopause, or after age 65, do not show the same protective effect, and some studies suggest a possible increased risk. This is the “critical window” or “timing hypothesis” — and it has significant implications for when women in our community should be having this conversation with their doctors.
The honest summary: hormone therapy, initiated at the right time, in the right formulation, for women without specific contraindications, appears to be a meaningful tool for reducing Alzheimer’s risk. It is not a guarantee. It is not the only tool. But it is far more supported by evidence than most women in Southern Oregon have been told.
“Estrogen is currently on the table. We have put ourselves in a difficult situation where now we need to re-educate not just the patients, but also the entire medical and scientific community.”
— Dr. Lisa Mosconi
What Is Available in Southern Oregon Right Now
So where can a woman in the Rogue Valley go if she wants a thoughtful, science-informed conversation about menopause, brain health, and hormone therapy?
The honest answer is: it depends on how hard she is willing to look, and how much she can afford.
Asante’s Rogue Regional Medical Center, the region’s dominant healthcare system, has a solid neurology department that handles stroke, epilepsy, Parkinson’s, and general cognitive disorders. Their outpatient neurology team diagnoses and treats a broad range of nervous system conditions. For women in the late stages of cognitive decline, or those who have already received a dementia diagnosis, Asante provides competent care. What Asante does not currently offer is a dedicated Alzheimer’s prevention clinic — a place where a 52-year-old woman with a family history and early symptoms can access comprehensive biomarker testing, brain imaging, and a personalized risk reduction plan.
Southern Oregon Gynecology (SOGYN) in Medford offers hormone consultations and is explicitly open to discussing menopause management including hormone replacement therapy — a meaningful step beyond many gynecology practices that remain reflexively cautious post-WHI. Women’s Health Center of Southern Oregon, with offices in Grants Pass and Ashland, similarly offers hormone therapy options. These are important resources, but they are primarily focused on symptom management — hot flashes, sleep, mood — rather than on the brain health dimension of hormone therapy.
The most sophisticated prevention-oriented cognitive care in the region comes from Dr. Deborah Gordon’s Northwest Wellness Center in Ashland. Dr. Gordon is genuinely exceptional — she is one of only three physicians in the country who served as a clinical investigator in Dr. Dale Bredesen’s landmark precision medicine trial for Alzheimer’s, which showed improvement in over 80% of early-stage patients using a comprehensive lifestyle and metabolic approach. Her work integrates nutrition, sleep, metabolic health, hormone status, environmental exposures, and brain biomarkers into a personalized plan. She is, by any measure, a national-level resource practicing in our backyard.
The problem: Dr. Gordon is reportedly not accepting new patients. And even if she were, her model — comprehensive, time-intensive, integrative, largely out-of-pocket — is inaccessible to the majority of women in Southern Oregon, particularly those in Josephine, Klamath, or Douglas counties, or those without the financial cushion to invest in care that insurance does not typically cover.
What Is Missing: The Structural Gaps
When you map the available resources against what the science says women need, several structural gaps emerge clearly:
- No dedicated Alzheimer’s prevention clinic. Weill Cornell has one. Cleveland Clinic has one. Southern Oregon — a region with over 79,000 people living with Alzheimer’s statewide and a disproportionately older rural population — does not.
- No routine brain health screening for midlife women. Women in their late 40s and early 50s are routinely screened for cervical cancer, breast cancer, colon cancer, and osteoporosis. No one is routinely checking their brain metabolism, their cognitive trajectory, or their hormonal environment in the context of long-term brain risk.
- Limited menopause-literate primary care. Most primary care physicians in our region — through no fault of their own — received training that treated the WHI as settled science. Many remain uncomfortable prescribing hormone therapy, or do not have the time or training to navigate the nuances of timing, formulation, and individual risk profile that the new evidence requires.
- An insurance system that rewards symptom management over prevention. A hot flash is a billable symptom. A 52-year-old woman asking about her 20-year brain health trajectory is not a standard reimbursable encounter. The incentives point away from prevention and toward treating established disease.
- Geographic and economic barriers. The integrative, precision medicine approach to brain health that Dr. Mosconi and Dr. Bredesen represent requires time, testing, follow-up, and often out-of-pocket investment. For the working-class and rural populations that make up a significant portion of Southern Oregon, this model is effectively unavailable.
What Can You Do Right Now
While our healthcare system catches up to the science, there are concrete steps that women in Southern Oregon can take today:
- Have the conversation. Tell your primary care doctor or gynecologist that you want to discuss the relationship between menopause and brain health. Bring this article if you need to. The Alzheimer’s Association’s 24/7 helpline (800-272-3900) can help connect you with local resources.
- Ask about hormone therapy timing. If you are in perimenopause or early postmenopause (within 10 years of your last period), ask about the evidence for hormone therapy and Alzheimer’s prevention — not just symptom relief. Find a provider willing to have that conversation.
- Know your genetic risk. APOE4 testing is available through standard genetic testing services. If you have a strong family history of Alzheimer’s, this information — combined with a knowledgeable provider — can help you prioritize prevention steps.
- Contact Northwest Wellness Center. Even if Dr. Gordon is not accepting new patients, her team may be able to offer guidance, resources, or a waiting list. Their number is (541) 482-8333.
- Advocate for structural change. This is the bigger ask — and it is the subject of our final article.
Next in this series: Article Three — What Southern Oregon Must Build: A Call for Structural Change in How We Approach Brain Health
This series was produced by Reimagine Healthcare (wp.reimagine-healthcare.org/) for educational purposes. It is based on research published in peer-reviewed journals and the publicly available work of Dr. Lisa Mosconi and colleagues. It is not intended as medical advice. Please consult a qualified healthcare provider for personal medical guidance.